{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:32:40Z","timestamp":1782563560717,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["4011418"],"award-info":[{"award-number":["4011418"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.diagmicrobio.2025.116806","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T03:37:46Z","timestamp":1742009866000},"page":"116806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Investigating the susceptibility profiles and in vitro combinations of caspofungin, itraconazole, fluconazole, voriconazole, clotrimazole, and amphotericin B against clinical isolates causing fungal keratitis"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9694-2873","authenticated-orcid":false,"given":"Shaghayegh","family":"Moghadam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1449-4668","authenticated-orcid":false,"given":"Hossein","family":"Zarrinfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Naseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Najafzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozhan","family":"Heydarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.diagmicrobio.2025.116806_bib0001","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.2021.0424","article-title":"Infectious keratitis in 2021","volume":"326","author":"Durand","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116806_bib0002","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.survophthal.2018.12.003","article-title":"The persistent dilemma of microbial keratitis: global burden, diagnosis, and antimicrobial resistance","volume":"64","author":"Ung","year":"2019","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2025.116806_bib0003","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2471\/BLT.19.232660","article-title":"Infectious corneal ulceration: a proposal for neglected tropical disease status","volume":"97","author":"Ung","year":"2019","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108372","article-title":"The role of fungi in fungal keratitis","volume":"202","author":"Mills","year":"2021","journal-title":"Exp Eye Res"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2025.116806_bib0005","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/myc.12822","article-title":"Fungal keratitis: an overview of clinical and laboratory aspects","volume":"61","author":"Mahmoudi","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.698780","article-title":"Distribution, prevalence, and causative agents of fungal keratitis: a systematic review and meta-analysis (1990 to 2020)","volume":"11","author":"Ahmadikia","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0007","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.mmcr.2013.03.002","article-title":"An environmental Sporothrix as a cause of corneal ulcer","volume":"2","author":"Morrison","year":"2013","journal-title":"Med Mycol Case Rep"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116806_bib0008","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/01.ico.0000177423.77648.8d","article-title":"Fungal keratitis at the New York eye and ear infirmary","volume":"25","author":"Ritterband","year":"2006","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116806_bib0009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00003226-200005000-00010","article-title":"Spectrum of fungal keratitis at Wills eye hospital, Philadelphia, Pennsylvania","volume":"19","author":"Tanure","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0010","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s11046-016-0042-3","article-title":"Fungal keratitis in North India: spectrum of agents, risk factors and treatment","volume":"181","author":"Ghosh","year":"2016","journal-title":"Mycopathologia"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2025.116806_bib0011","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/sj.eye.6700557","article-title":"Fungal infections of the cornea","volume":"17","author":"Thomas","year":"2003","journal-title":"Eye"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2025.116806_bib0012","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/jof8090962","article-title":"Fungal keratitis: clinical features, risk factors, treatment, and outcomes","volume":"8","author":"Atta","year":"2022","journal-title":"J Fungi"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0013","unstructured":"Castano G, Elnahry AG, Mada PK. Fungal keratitis. 2018."},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116806_bib0014","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.survophthal.2021.08.002","article-title":"Fungal keratitis: mechanisms of infection and management strategies","volume":"67","author":"Donovan","year":"2022","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116806_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40794-023-00194-w","article-title":"Antifungal activity of three different varieties of Capsicum annuum against clinical isolates of Candida species","volume":"9","author":"Moghadam","year":"2023","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0016","first-page":"123","article-title":"Antifungal activity of curcuminoids and difluorinated curcumin against clinical isolates of Candida species","author":"Azari","year":"2021","journal-title":"Nat Prod Hum Dis: Pharmacol, Mol Targets, Therapeut Benefits"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0017","first-page":"27","article-title":"Comparison of antifungal activities of zinc, copper, cerium oxide, silver, gold, and selenium nanoparticles against clinical isolates of Aspergillus","volume":"25","author":"Moghadam","year":"2023","journal-title":"Synthesis"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2025.116806_bib0018","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/jof7110907","article-title":"Recent perspectives in the management of fungal keratitis","volume":"7","author":"Raj","year":"2021","journal-title":"J Fungi"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0019","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jtos.2021.12.001","article-title":"Fungal keratitis: a review of clinical presentations, treatment strategies and outcomes","volume":"24","author":"Sharma","year":"2022","journal-title":"Ocul Surf"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.116806_bib0020","article-title":"Medical interventions for fungal keratitis","volume":"2015","author":"FlorCruz","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12281-013-0150-1","article-title":"Current thoughts in fungal keratitis: diagnosis and treatment","volume":"7","author":"Ansari","year":"2013","journal-title":"Curr Fungal Infect Rep"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.116806_bib0022","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ophtha.2005.10.063","article-title":"Risk factors for treatment outcome in fungal keratitis","volume":"113","author":"Lalitha","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0023","article-title":"Causative agents of fungal keratitis in northeastern Iran: A 3-year tertiary care hospital study","author":"Moghadam","year":"2024","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0024","series-title":"CLSI document M27-A2","article-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard","author":"PA","year":"2002"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2025.116806_bib0025","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1128\/JCM.00399-07","article-title":"Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds","volume":"45","author":"Espinel-Ingroff","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0026","doi-asserted-by":"crossref","unstructured":"Subbiah V. Antifungal agents. Methods and protocols Edited by E. J. Ernst and P. D. Rogers (University of Iowa and University of Tennessee, respectively). Humana Press, Totowa, NJ. 2005. x + 209 pp. 6 \u00d7 9 in. $99.50. ISBN 1-588-29-277-0. Journal of Natural Products. 2005;68(11):1713-.","DOI":"10.1021\/np058260n"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0027","series-title":"European committee on antimicrobial susceptibility testing (EUCAST) technical notes on antimicrobial susceptibility testing","first-page":"501","author":"Kahlmeter","year":"2006"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2025.116806_bib0028","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1128\/JCM.00248-12","article-title":"Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution","volume":"50","author":"Pfaller","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2025.116806_bib0029","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jiph.2020.10.014","article-title":"In-vitro assessment of first-line antifungal drugs against Aspergillus spp. Caused human keratomycoses","volume":"13","author":"Hassan","year":"2020","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11046-021-00537-1","article-title":"Molecular identification and antifungal susceptibility of yeasts and molds isolated from patients with otomycosis","volume":"186","author":"Kiakojuri","year":"2021","journal-title":"Mycopathologia"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116806_bib0031","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1439-0507.2012.02194.x","article-title":"Epidemiology of Aspergillus keratitis at a tertiary care eye hospital in South India and antifungal susceptibilities of the causative agents","volume":"56","author":"Manikandan","year":"2013","journal-title":"Mycoses"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116806_bib0032","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/myc.13550","article-title":"In vitro antifungal susceptibility profile of Iranian Fusarium isolates: emphasising on the potent inhibitory effect of efinaconazole compared to other drugs","volume":"66","author":"Nosratabadi","year":"2023","journal-title":"Mycoses"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116806_bib0033","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.mycmed.2014.10.024","article-title":"In vitro susceptibility of filamentous fungi from mycotic keratitis to azole drugs","volume":"25","author":"Shobana","year":"2015","journal-title":"J Mycol Med"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2025.116806_bib0034","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/jof8070709","article-title":"In vitro antifungal susceptibility profile of miltefosine against a collection of azole and echinocandins resistant Fusarium strains","volume":"8","author":"Nosratabadi","year":"2022","journal-title":"J Fungi"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116806_bib0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/jof3020019","article-title":"Antifungal susceptibility testing of Fusarium: a practical approach","volume":"3","author":"Al-Hatmi","year":"2017","journal-title":"J Fungi"},{"issue":"10.5772","key":"10.1016\/j.diagmicrobio.2025.116806_bib0036","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.98411","article-title":"Fungal keratitis: recent advances in diagnosis and treatment","volume":"55","author":"Suman","year":"2021","journal-title":"Infect Eye Dis Recent Adv Diagn Treat."},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116806_bib0037","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4103\/0301-4738.185592","article-title":"Recent advances in diagnosis and management of Mycotic keratitis","volume":"64","author":"Maharana","year":"2016","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2025.116806_bib0038","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/archophthalmol.2010.102","article-title":"Comparison of natamycin and voriconazole for the treatment of fungal keratitis","volume":"128","author":"Prajna","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116806_bib0039","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.46.3.940-940.2002","article-title":"Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations","volume":"46","author":"Nelson","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116806_bib0040","article-title":"Fungal keratitis: epidemiology, rapid detection, and antifungal susceptibilities of fusarium and Aspergillus isolates from corneal scrapings","volume":"2019","author":"Manikandan","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1094182","article-title":"Fungal keratitis in Iran: risk factors, clinical features, and mycological profile","volume":"13","author":"Soleimani","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116806_bib0042","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.riam.2013.01.002","article-title":"Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium","volume":"30","author":"Spader","year":"2013","journal-title":"Revista Iberoamericana de Micolog\u00eda"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.116806_bib0043","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jac\/dkv421","article-title":"In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical Fusarium strains causing keratitis","volume":"71","author":"Al-Hatmi","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116806_bib0044","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10384-022-00907-2","article-title":"Multicenter prospective observational study of fungal keratitis in Japan: analyses of in vitro susceptibility tests for combinations of drugs","volume":"66","author":"Kimura","year":"2022","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.diagmicrobio.2025.116806_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1038342","article-title":"In vitro and in vivo evaluation of antifungal combinations against azole-resistant Aspergillus fumigatus isolates","volume":"12","author":"Jemel","year":"2023","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325001294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325001294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:52:11Z","timestamp":1752573131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889325001294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0732889325001294"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116806","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the susceptibility profiles and in vitro combinations of caspofungin, itraconazole, fluconazole, voriconazole, clotrimazole, and amphotericin B against clinical isolates causing fungal keratitis","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116806"}}